Glucagon-like peptide-1 receptor agonists can improve blood glucose control and reduce weight in T2D patients, with some of them reducing the risk of cardiovascular (CV) events in patients with high CV risk. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.